Evidence map›Paper›PMID 38951531›Full record

ArticleNature communications2024

Structure and function of the SIT1 proline transporter in complex with the COVID-19 receptor ACE2.

Huanyu Z Li, Ashley C W Pike, Irina Lotsaris, Gamma Chi, Jesper S Hansen, Sarah C Lee, Karin E J Rödström, Simon R Bushell, David Speedman, Adam Evans and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?International journal of molecular sciences · 2025
    Review
  4. Unveiling the Structure of PROT and ATBMolecules (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Computational and structural biotechnology journal · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Huanyu Z LiCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-5482-9936
Ashley C W PikeCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9661-2607
Irina LotsarisMolecular Biomedicine Theme, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-5627-9897
Gamma ChiCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9910-0965
Jesper S HansenCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Sarah C LeeSchool of Biosciences, University of Birmingham, Birmingham, UK.
Karin E J RödströmCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Simon R BushellCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
David SpeedmanCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Adam EvansCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Dong WangCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-7379-357X
Didi HeCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Leela ShresthaCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Chady NasrallahCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nicola A Burgess-BrownCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Robert J VandenbergMolecular Biomedicine Theme, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia. robert.vandenberg@sydney.edu.au.ORCID 0000-0003-1523-4814
Timothy R DaffornSchool of Biosciences, University of Birmingham, Birmingham, UK. t.r.dafforn@bham.ac.uk.
Elisabeth P CarpenterCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK. lizcarpen1@gmail.com.
David B SauerCentre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK. david.sauer@cmd.ox.ac.uk.ORCID 0000-0001-9291-4640

Funding

Innovative Medicines Initiative (IMI) 875510RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/V018051/1Wellcome Trust
6 · The paper itself

Abstract

Proline is widely known as the only proteogenic amino acid with a secondary amine. In addition to its crucial role in protein structure, the secondary amino acid modulates neurotransmission and regulates the kinetics of signaling proteins. To understand the structural basis of proline import, we solved the structure of the proline transporter SIT1 in complex with the COVID-19 viral receptor ACE2 by cryo-electron microscopy. The structure of pipecolate-bound SIT1 reveals the specific sequence requirements for proline transport in the SLC6 family and how this protein excludes amino acids with extended side chains. By comparing apo and substrate-bound SIT1 states, we also identify the structural changes that link substrate release and opening of the cytoplasmic gate and provide an explanation for how a missense mutation in the transporter causes iminoglycinuria.

Indexed as

Angiotensin-Converting Enzyme 2Cryoelectron MicroscopyProlineSARS-CoV-2Amino Acid Transport Systems, NeutralCOVID-19HumansModels, MolecularACE2 protein, humanAmino Acid Transport Systems, NeutralAngiotensin-Converting Enzyme 2ProlineSLC6A19 protein, human

Identifiers

PMID38951531
PMCPMC11217458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.